Is 5-25-11-00364 (Beilstein Handbook Reference) Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use 5-25-11-00364 (Beilstein Handbook Reference)? Is 5-25-11-00364 (Beilstein Handbook Reference) safe for nursing mother and child? Does 5-25-11-00364 (Beilstein Handbook Reference) extracts into breast milk? Does 5-25-11-00364 (Beilstein Handbook Reference) has any long term or short term side effects on infants? Can 5-25-11-00364 (Beilstein Handbook Reference) influence milk supply or can 5-25-11-00364 (Beilstein Handbook Reference) decrease milk supply in lactating mothers?

We are working on a comment for this product.

Because there is little published experience with 5-25-11-00364 (Beilstein Handbook Reference) during breastfeeding, and sedation and adverse hematologic effects have been reported in breastfed infants, other agents are preferred.[1] If breastfeeding is undertaken by a mother who is taking 5-25-11-00364 (Beilstein Handbook Reference), close monitoring of the infant for excessive sedation and periodic monitoring of the infant's white blood cell count is advisable. Several authoritative sources recommend that women taking 5-25-11-00364 (Beilstein Handbook Reference) not breastfeed.[2][3][4]

Among 4 infants who were breastfed by mothers taking 5-25-11-00364 (Beilstein Handbook Reference), 1 infant experienced drowsiness and 1 infant experienced agranulocytosis possibly caused by 5-25-11-00364 (Beilstein Handbook Reference). Details of the cases are lacking.[7] A healthy female infant was born to a mother who took 5-25-11-00364 (Beilstein Handbook Reference) 100 mg daily throughout pregnancy and lactation. She was breastfed (extent not stated) up to 1 year of age. The infant developed normally except for speech which was delayed considerably. She did not achieve normal, fluent speech until the age of 5 years. The delayed speech development was possibly related to 5-25-11-00364 (Beilstein Handbook Reference) in breastmilk, but it could have been the result of exposure to the drug during gestation or could have been unrelated to 5-25-11-00364 (Beilstein Handbook Reference).[8] One woman who took 5-25-11-00364 (Beilstein Handbook Reference) 100 mg daily in late pregnancy and postpartum partially breastfed her infant for 5 days. No neurodevelopmental disorders were detected in the infant after 32 months of follow-up.[6]

Unlike the phenothiazines, 5-25-11-00364 (Beilstein Handbook Reference) has a minimal effect on maternal serum prolactin levels.[9][10] However, a woman who had been taking 5-25-11-00364 (Beilstein Handbook Reference) plus high-dose haloperidol developed hyperprolactinemia and severe galactorrhea 2 weeks after stopping haloperidol and 4 days after starting valproic acid. A dose of cabergoline normalized her serum prolactin and galactorrhea ceased for the following 2 months of observation.[11] The maternal prolactin level in a mother with established lactation may not affect her ability to breastfeed.